시신경 척수염 역학 분석과 예측(2026년)

The Global Neuromyelitis Optica prevelance is forecast to grow at a CAGR of 3.1%, reaching 0.27 million patients in 2035 from 0.20 million patients in 2026.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system that primarily affects the optic nerves and spinal cord, leading to recurrent episodes of optic neuritis, transverse myelitis, paralysis, visual impairment, and long-term neurological disability. The discovery of aquaporin-4 (AQP4) antibodies has significantly improved diagnostic accuracy and disease classification, allowing better differentiation from multiple sclerosis and supporting more reliable epidemiological assessments. As awareness and diagnostic capabilities continue to improve, epidemiology analysis has become increasingly important for healthcare planning, clinical trial recruitment, commercial forecasting, and rare disease management.

Epidemiology analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic distribution, serological subtypes, regional disease burden, and long-term patient forecasts. These analyses support pharmaceutical companies, biotechnology firms, healthcare providers, policymakers, researchers, and investors in evaluating treatment opportunities and planning future healthcare strategies.

Market Drivers

Growing Disease Awareness and Improved Diagnosis

• One of the primary drivers of market growth is the increasing recognition of NMOSD as a distinct autoimmune neurological disorder. Greater physician awareness, updated diagnostic criteria, and widespread availability of AQP4 antibody testing have significantly improved diagnosis rates and reduced misclassification with multiple sclerosis.
• Earlier diagnosis enables more accurate epidemiological tracking and supports timely therapeutic intervention.

Expansion of Epidemiological Research

• Growing investments in rare disease registries, observational studies, and population-based research are improving the quality of epidemiological data worldwide. National registries and international collaborations are generating more comprehensive information regarding disease prevalence, incidence, patient demographics, and long-term outcomes.
• These initiatives are strengthening disease surveillance and supporting evidence-based healthcare planning.

Increasing Demand for Precision Medicine

• The emergence of targeted biologic therapies has increased the need for detailed patient segmentation based on antibody status, disease severity, age, gender, and geographic distribution.
• Accurate epidemiological analysis enables pharmaceutical companies to estimate eligible patient populations, optimize clinical trial recruitment, and support commercialization strategies.

Advancements in Diagnostic Technologies

• Improvements in antibody assays, magnetic resonance imaging (MRI), molecular diagnostics, and biomarker identification are enhancing case detection and reducing diagnostic delays.
• The adoption of high-sensitivity laboratory testing continues to improve epidemiological accuracy across both developed and emerging healthcare markets.

Market Restraints

Rare Disease Status

• NMOSD remains a relatively uncommon neurological disorder, limiting the availability of large-scale epidemiological datasets and creating challenges for long-term population forecasting.

Regional Variability in Diagnosis

• Differences in healthcare infrastructure, access to specialist care, diagnostic capabilities, and reporting systems contribute to variations in disease identification across countries and regions.

Limited Long-Term Data

• Although epidemiological research has expanded considerably, long-term natural history data remain limited in many regions, particularly within low- and middle-income countries.

Epidemiology and Patient Population Insights

• The global burden of NMOSD remains relatively low compared with other neurological disorders; however, the disease has a significant impact on patients due to its chronic, relapsing nature and potential for severe disability.
• Current epidemiological studies estimate that NMOSD prevalence generally ranges from approximately 0.5 to 10 cases per 100,000 population, while annual incidence ranges from 0.03 to 0.88 cases per 100,000 population, with considerable variation across geographic regions and ethnic groups. Higher prevalence has been reported among individuals of African and Asian ancestry, while lower prevalence has generally been observed in White populations.
• Women account for the majority of NMOSD cases, particularly among AQP4 antibody-positive patients, with disease onset most commonly occurring during middle adulthood. The prevalence of AQP4-seropositive disease is substantially higher than seronegative disease across most studied populations.
• As improvements in diagnostic testing and disease awareness continue, the diagnosed patient population is expected to increase steadily throughout the forecast period.

Technology and Segment Insights

• The global NMOSD epidemiology analysis market can be segmented by disease subtype, antibody status, age group, gender, data source, end user, and geography.
• By disease subtype, the market includes AQP4 antibody-positive NMOSD, myelin oligodendrocyte glycoprotein (MOG)-associated disease, seronegative NMOSD, and related autoimmune demyelinating disorders.
• By antibody status, the market includes AQP4-positive, MOG-positive, and double-seronegative patient populations. AQP4-positive patients currently represent the largest epidemiological segment.
• By age group, the market includes pediatric, adult, and elderly patient populations. Adult patients account for the largest share, although pediatric cases remain clinically significant.
• By gender, the market includes male and female populations, with females representing a substantially higher proportion of diagnosed patients.
• By data source, the market includes hospital databases, electronic health records, patient registries, insurance claims databases, laboratory databases, and population-based epidemiological studies.
• By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms.
• Advancements in artificial intelligence, predictive analytics, digital health platforms, and real-world evidence systems are improving patient identification, disease surveillance, and long-term epidemiological forecasting.

Regional Insights

• North America remains a leading market for NMOSD epidemiology analysis due to advanced diagnostic infrastructure, established patient registries, and strong rare disease research programs.
• Europe represents another significant market supported by collaborative neurological research networks, comprehensive healthcare systems, and increasing epidemiological surveillance.
• Asia-Pacific is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, increasing availability of antibody testing, expanding clinical research activity, and rising awareness of autoimmune neurological disorders. Countries such as Japan, China, South Korea, and India continue to strengthen rare disease diagnosis and reporting capabilities.
• Latin America and the Middle East & Africa are gradually improving epidemiological surveillance through expanding healthcare access, improved laboratory diagnostics, and participation in international rare disease research initiatives.

Competitive Landscape

• The competitive landscape includes epidemiology research organizations, healthcare analytics providers, patient registry operators, academic research institutions, pharmaceutical companies, biotechnology firms, and healthcare consulting organizations.
• Industry participants continue to invest in disease registries, real-world evidence generation, digital epidemiology platforms, biomarker research, and advanced healthcare analytics. Strategic collaborations between pharmaceutical companies, academic centers, patient advocacy organizations, and government agencies are improving data quality and strengthening epidemiological research capabilities.

Future Outlook

• The future NMOSD epidemiology analysis market is expected to be driven by continued improvements in diagnostic technologies, expansion of global patient registries, increasing adoption of precision medicine, and greater integration of real-world evidence into healthcare decision-making.
• Artificial intelligence, genomic analytics, biomarker discovery, and digital disease surveillance platforms are expected to enhance epidemiological forecasting and improve understanding of disease burden across different populations.
• As awareness continues to increase and diagnostic capabilities improve worldwide, more accurate estimates of disease prevalence, incidence, and patient demographics are expected to support clinical development and healthcare planning.

Conclusion

• The global Neuromyelitis Optica epidemiology analysis market is poised for steady growth through 2035, supported by expanding epidemiological research, improved diagnostic technologies, increasing disease awareness, and growing investment in rare neurological disease management. Although NMOSD remains a rare disorder, advances in antibody testing, patient registries, real-world evidence, and digital health technologies are significantly improving disease surveillance and patient identification. As more comprehensive epidemiological data become available, stakeholders across the healthcare ecosystem will be better positioned to support clinical research, optimize healthcare resource allocation, and improve long-term patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global NMOSD prevalence, incidence, diagnosed patient populations, and epidemiological trends.
• Competitive Landscape: Understand regional disease burden, patient demographics, and evolving epidemiological research.
• Market Drivers and Future Trends: Assess factors influencing disease diagnosis, patient identification, and future population growth.
• Actionable Recommendations: Support healthcare planning, clinical trial recruitment, commercialization strategies, and investment decisions.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, investors, and policymakers.

What Businesses Use Our Reports For

• Epidemiological forecasting, patient population assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, rare disease strategy development, investment analysis, and commercialization planning.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Global, regional, and country-level epidemiological analysis and forecasts
• Prevalence, incidence, diagnosed patient population, and demographic segmentation
• Disease subtype, antibody status, and regional burden assessment
• Competitive intelligence, patient registry analysis, and future market opportunity outlook.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
• 1.2 Key Findings
• 1.3 Epidemiology Snapshot of Neuromyelitis Optica Spectrum Disorder (NMOSD)
• 1.4 Incidence and Prevalence Highlights
• 1.5 Treatment Landscape Overview
• 1.6 Pipeline and Innovation Snapshot
• 1.7 Key Growth Opportunities
• 1.8 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Neuromyelitis Optica Spectrum Disorder (NMOSD)
• 2.2 Disease Definition and Clinical Characteristics
• 2.3 Historical Evolution of Disease Classification
• 2.4 Etiology and Risk Factors
• 2.5 Immunopathogenesis
  • 2.5.1 Autoimmune Mechanisms
  • 2.5.2 Role of Aquaporin-4 (AQP4) Antibodies
  • 2.5.3 Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease and Differentiation
• 2.6 Disease Signs and Symptoms
• 2.7 Diagnostic Criteria and Guidelines
• 2.8 Disease Burden and Quality of Life Impact
• 2.9 Epidemiology Overview
  • 2.9.1 Total Prevalent Cases
  • 2.9.2 Total Incident Cases
  • 2.9.3 Diagnosed Prevalent Cases
  • 2.9.4 Gender-wise Epidemiology
  • 2.9.5 Age-wise Epidemiology
  • 2.9.6 AQP4-IgG Positive Population
  • 2.9.7 AQP4-IgG Negative Population
  • 2.9.8 MOG Antibody-associated Disease Population
• 2.10 Epidemiology Forecast

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Disease Awareness and Diagnosis Rates
  • 3.2.2 Increasing Availability of Targeted Biologics
  • 3.2.3 Advancements in Diagnostic Technologies
• 3.3 Market Restraints
  • 3.3.1 High Treatment Costs
  • 3.3.2 Limited Access in Emerging Markets
  • 3.3.3 Diagnostic Challenges in Rare Diseases
• 3.4 Market Opportunities
  • 3.4.1 Expansion of Novel Immunotherapies
  • 3.4.2 Biomarker-based Personalized Medicine
  • 3.4.3 Emerging Markets Penetration
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Pricing Analysis
• 4.3 Reimbursement Scenario
• 4.4 Health Technology Assessment (HTA) Trends
• 4.5 Patient Assistance Programs
• 4.6 Rare Disease Funding Initiatives
• 4.7 Distribution and Supply Chain Overview

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Emerging Therapeutic Approaches
  • 5.2.1 Complement Inhibitors
  • 5.2.2 Anti-CD19 Therapies
  • 5.2.3 Anti-IL-6 Receptor Therapies
  • 5.2.4 FcRn Inhibitors
• 5.3 Pipeline Landscape Overview
• 5.4 Phase I Pipeline Candidates
• 5.5 Phase II Pipeline Candidates
• 5.6 Phase III Pipeline Candidates
• 5.7 Pipeline by Mechanism of Action
• 5.8 Pipeline by Modality
  • 5.8.1 Monoclonal Antibodies
  • 5.8.2 Recombinant Proteins
  • 5.8.3 Biologics
• 5.9 Clinical Trial Landscape
• 5.10 Licensing, Collaborations, and Strategic Alliances

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Attack Management
  • 6.2.1 Corticosteroids
  • 6.2.2 Plasma Exchange
  • 6.2.3 Intravenous Immunoglobulin
• 6.3 Maintenance Therapy
• 6.4 Approved Therapies Overview
  • 6.4.1 Soliris (eculizumab)
  • 6.4.2 Ultomiris (ravulizumab)
  • 6.4.3 Uplizna (inebilizumab)
  • 6.4.4 Enspryng (satralizumab)
• 6.5 Treatment Algorithm
• 6.6 Unmet Clinical Needs
• 6.7 Future Treatment Trends

7. Global Neuromyelitis Optica Epidemiology Report Size & Forecast

• 7.1 Market Size Overview
• 7.2 Historical Market Analysis
• 7.3 Forecast Methodology
• 7.4 Market Forecast by Value
• 7.5 Market Forecast by Volume
• 7.6 Epidemiology-based Market Forecast
• 7.7 Market Attractiveness Analysis

8. Global Neuromyelitis Optica Epidemiology Report Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Relapse Treatment
  • 8.1.2 Maintenance Therapy
• 8.2 By Drug Class
  • 8.2.1 Complement Inhibitors
  • 8.2.2 B-Cell Depleting Therapies
  • 8.2.3 Anti-IL-6 Receptor Monoclonal Antibodies
  • 8.2.4 Others
• 8.3 By Indication
  • 8.3.1 AQP4-IgG Positive NMOSD
  • 8.3.2 AQP4-IgG Negative NMOSD
• 8.4 By Route of Administration
  • 8.4.1 Intravenous
  • 8.4.2 Subcutaneous
  • 8.4.3 Oral
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Clinics
  • 8.5.3 HomeCare Settings
  • 8.5.4 Others
• 8.6 By Distribution Channel
  • 8.6.1 Hospital Pharmacies
  • 8.6.2 Retail & Specialty Pharmacies
  • 8.6.4 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Epidemiology Trends
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Epidemiology Trends
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Epidemiology Trends
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Epidemiology Trends
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Epidemiology Trends
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 United States - FDA Framework
• 11.3 Europe - EMA and Orphan Drug Regulations
• 11.4 Japan - PMDA Regulatory Framework
• 11.5 India - CDSCO and Rare Disease Policies
• 11.6 China - NMPA Regulatory Framework
• 11.7 Orphan Drug Designation and Incentives
• 11.8 Pricing and Reimbursement Policies
• 11.9 Future Regulatory Trends

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Positioning Analysis
• 12.4 Pipeline Competitiveness Assessment
• 12.5 Strategic Initiatives
  • 12.5.1 Partnerships and Collaborations
  • 12.5.2 Mergers and Acquisitions
  • 12.5.3 Licensing Agreements
  • 12.5.4 Geographic Expansion Strategies

13. Company Profiles

• 13.1 AstraZeneca
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products: Soliris (eculizumab), Ultomiris (ravulizumab)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Overview
• 13.2 Amgen
  • 13.2.1 Company Overview
  • 13.2.2 Approved Product: Uplizna (inebilizumab)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Overview
• 13.3 Roche Holding
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product: Enspryng (satralizumab)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Overview
• 13.4 Chugai Pharmaceutical
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product: Enspryng (satralizumab)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Overview
• 13.5 Mitsubishi Tanabe Pharma Corporation
  • 13.5.1 Company Overview
  • 13.5.2 Approved Product Portfolio
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Overview
• 13.6 Argenx
  • 13.6.1 Company Overview
  • 13.6.2 Pipeline Candidate: efgartigimod
  • 13.6.3 Clinical Development Status
  • 13.6.4 Strategic Outlook
• 13.7 HanAll Biopharma
  • 13.7.1 Company Overview
  • 13.7.2 Pipeline Candidate: batoclimab
  • 13.7.3 Clinical Development Status
  • 13.7.4 Strategic Outlook
• 13.8 Alexion Pharmaceuticals
  • 13.8.1 Company Overview
  • 13.8.2 Approved Products Portfolio
  • 13.8.3 Key Indications
  • 13.8.4 Strategic Developments
• 13.9 Horizon Therapeutics
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products Portfolio
  • 13.9.3 Key Indications
  • 13.9.4 Strategic Developments
• 13.10 Viela Bio
  • 13.10.1 Company Overview
  • 13.10.2 Approved Product: Uplizna (inebilizumab)
  • 13.10.3 Key Indications
  • 13.10.4 Historical and Strategic Developments

14. Future Outlook

• 14.1 Market Growth Outlook
• 14.2 Emerging Treatment Trends
• 14.3 Pipeline-driven Market Evolution
• 14.4 Personalized Medicine Prospects
• 14.5 Competitive Outlook
• 14.6 Strategic Recommendations

15. Methodology

• 15.1 Research Methodology
• 15.2 Data Sources
• 15.3 Epidemiology Modeling Approach
• 15.4 Forecasting Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Assumptions and Limitations
• 15.7 Abbreviations and Definitions